drugset / Trial / NCT02892942
NATural Ovarian Stimulation
Phase 4
Completed
129 enrolled
Assistance Publique - Hôpitaux de Paris
MerckSerono Pharmaceuticals · collabURC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To overcome unsuitable effects of controlled ovarian hyperstimulation (COH )while maintaining large oocyte availability, investigators elaborated an innovative protocol (NATural Ovarian Stimulation) that dissociates E2 production from multiple follicle development. The purpose of this prospective, randomized trial is to demonstrate that, in a good prognosis IVF-ET population, the physiological E2 environment resulting from NATOS significantly improves IVF-ET outcome when compared to the conventional GnRH antagonist protocol.
Timeline
- Start
- 2017-01-13
- Primary completion
- 2019-02-08
- Completion
- 2019-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetrorelix | Other / unclassified | 0.25 mg | Subcutaneous |
| Subject | Cetrorelix | Other / unclassified | 1.5 mg | Subcutaneous |
| Background | Gonal-f | Protein / enzyme biologic | 225 iu | — |
| Background | Gonal-f | Protein / enzyme biologic | 450 iu | — |